Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo.

Staudacher AH, Li Y, Liapis V, Hou JJC, Chin D, Dolezal O, Adams TE, van Berkel PH, Brown MP.

Mol Cancer Ther. 2019 Feb;18(2):335-345. doi: 10.1158/1535-7163.MCT-18-0842. Epub 2018 Nov 9.

PMID:
30413648
2.

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.

Cho S, Zammarchi F, Williams DG, Havenith CEG, Monks NR, Tyrer P, D'Hooge F, Fleming R, Vashisht K, Dimasi N, Bertelli F, Corbett S, Adams L, Reinert HW, Dissanayake S, Britten CE, King W, Dacosta K, Tammali R, Schifferli K, Strout P, Korade M 3rd, Masson Hinrichs MJ, Chivers S, Corey E, Liu H, Kim S, Bander NH, Howard PW, Hartley JA, Coats S, Tice DA, Herbst R, van Berkel PH.

Mol Cancer Ther. 2018 Oct;17(10):2176-2186. doi: 10.1158/1535-7163.MCT-17-0982. Epub 2018 Jul 31.

3.

Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine.

Hartley JA, Flynn MJ, Bingham JP, Corbett S, Reinert H, Tiberghien A, Masterson LA, Antonow D, Adams L, Chowdhury S, Williams DG, Mao S, Harper J, Havenith CEG, Zammarchi F, Chivers S, van Berkel PH, Howard PW.

Sci Rep. 2018 Jul 11;8(1):10479. doi: 10.1038/s41598-018-28533-4.

4.

ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.

Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N, Marafioti T, Britten CE, Havenith CEG, Chivers S, D'Hooge F, Williams DG, Tiberghien A, Howard PW, Hartley JA, van Berkel PH.

Blood. 2018 Mar 8;131(10):1094-1105. doi: 10.1182/blood-2017-10-813493. Epub 2018 Jan 3.

PMID:
29298756
5.

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.

Flynn MJ, Zammarchi F, Tyrer PC, Akarca AU, Janghra N, Britten CE, Havenith CE, Levy JN, Tiberghien A, Masterson LA, Barry C, D'Hooge F, Marafioti T, Parren PW, Williams DG, Howard PW, van Berkel PH, Hartley JA.

Mol Cancer Ther. 2016 Nov;15(11):2709-2721. Epub 2016 Aug 17.

6.

Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation.

van den Bremer ET, Beurskens FJ, Voorhorst M, Engelberts PJ, de Jong RN, van der Boom BG, Cook EM, Lindorfer MA, Taylor RP, van Berkel PH, Parren PW.

MAbs. 2015;7(4):672-80. doi: 10.1080/19420862.2015.1046665.

7.

High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates.

de Goeij BE, Satijn D, Freitag CM, Wubbolts R, Bleeker WK, Khasanov A, Zhu T, Chen G, Miao D, van Berkel PH, Parren PW.

Mol Cancer Ther. 2015 May;14(5):1130-40. doi: 10.1158/1535-7163.MCT-14-0798. Epub 2015 Feb 27.

8.

Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches.

Gramer MJ, van den Bremer ET, van Kampen MD, Kundu A, Kopfmann P, Etter E, Stinehelfer D, Long J, Lannom T, Noordergraaf EH, Gerritsen J, Labrijn AF, Schuurman J, van Berkel PH, Parren PW.

MAbs. 2013 Nov-Dec;5(6):962-73. doi: 10.4161/mabs.26233. Epub 2013 Aug 22.

9.

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW.

Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5145-50. doi: 10.1073/pnas.1220145110. Epub 2013 Mar 11.

10.

Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG.

Rose RJ, van Berkel PH, van den Bremer ET, Labrijn AF, Vink T, Schuurman J, Heck AJ, Parren PW.

MAbs. 2013 Mar-Apr;5(2):219-28. doi: 10.4161/mabs.23532. Epub 2013 Feb 13.

11.

Online nanoliquid chromatography-mass spectrometry and nanofluorescence detection for high-resolution quantitative N-glycan analysis.

Kalay H, Ambrosini M, van Berkel PH, Parren PW, van Kooyk Y, García Vallejo JJ.

Anal Biochem. 2012 Apr 1;423(1):153-62. doi: 10.1016/j.ab.2012.01.015. Epub 2012 Jan 28.

PMID:
22330744
12.

Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry.

Rose RJ, Labrijn AF, van den Bremer ET, Loverix S, Lasters I, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW, Heck AJ.

Structure. 2011 Sep 7;19(9):1274-82. doi: 10.1016/j.str.2011.06.016.

13.

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.

Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.

J Immunol Methods. 2011 Oct 28;373(1-2):67-78. doi: 10.1016/j.jim.2011.08.003. Epub 2011 Aug 9.

PMID:
21855548
14.

Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains.

Lammerts van Bueren JJ, Rispens T, Verploegen S, van der Palen-Merkus T, Stapel S, Workman LJ, James H, van Berkel PH, van de Winkel JG, Platts-Mills TA, Parren PW.

Nat Biotechnol. 2011 Jul 11;29(7):574-6. doi: 10.1038/nbt.1912. No abstract available.

PMID:
21747378
15.

Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose.

Gramer MJ, Eckblad JJ, Donahue R, Brown J, Shultz C, Vickerman K, Priem P, van den Bremer ET, Gerritsen J, van Berkel PH.

Biotechnol Bioeng. 2011 Jul;108(7):1591-602. doi: 10.1002/bit.23075. Epub 2011 Feb 18.

PMID:
21328321
16.

Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage.

Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, Parren PW, van de Winkel JG, Valerius T, Dechant M.

J Immunol. 2010 Jan 1;184(1):512-20. doi: 10.4049/jimmunol.0900847. Epub 2009 Nov 30.

17.

Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system.

van Berkel PH, Gerritsen J, van Voskuilen E, Perdok G, Vink T, van de Winkel JG, Parren PW.

Biotechnol Bioeng. 2010 Feb 1;105(2):350-7. doi: 10.1002/bit.22535.

PMID:
19739094
18.

N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG.

van Berkel PH, Gerritsen J, Perdok G, Valbjørn J, Vink T, van de Winkel JG, Parren PW.

Biotechnol Prog. 2009 Jan-Feb;25(1):244-51. doi: 10.1002/btpr.92.

PMID:
19224598
19.

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.

Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker WW, Dechant M, Beyer T, Repp R, van Berkel PH, Vink T, van de Winkel JG, Parren PW, Valerius T.

Blood. 2008 Sep 15;112(6):2390-9. doi: 10.1182/blood-2008-03-144600. Epub 2008 Jun 19.

PMID:
18566325
20.

N-glycans of recombinant human acid alpha-glucosidase expressed in the milk of transgenic rabbits.

Jongen SP, Gerwig GJ, Leeflang BR, Koles K, Mannesse ML, van Berkel PH, Pieper FR, Kroos MA, Reuser AJ, Zhou Q, Jin X, Zhang K, Edmunds T, Kamerling JP.

Glycobiology. 2007 Jun;17(6):600-19. Epub 2007 Feb 9.

PMID:
17293352
21.

Characterization of bovine neutrophil gelatinase-associated lipocalin.

van Veen HA, Geerts ME, Zoetemelk RA, Nuijens JH, van Berkel PH.

J Dairy Sci. 2006 Sep;89(9):3400-7.

22.

The protein structure of recombinant human lactoferrin produced in the milk of transgenic cows closely matches the structure of human milk-derived lactoferrin.

Thomassen EA, van Veen HA, van Berkel PH, Nuijens JH, Abrahams JP.

Transgenic Res. 2005 Aug;14(4):397-405.

PMID:
16201406
23.

Influence of lactation parameters on the N-glycosylation of recombinant human C1 inhibitor isolated from the milk of transgenic rabbits.

Koles K, van Berkel PH, Mannesse ML, Zoetemelk R, Vliegenthart JF, Kamerling JP.

Glycobiology. 2004 Nov;14(11):979-86. Epub 2004 Jul 14.

PMID:
15253928
24.

The role of N-linked glycosylation in the protection of human and bovine lactoferrin against tryptic proteolysis.

van Veen HA, Geerts ME, van Berkel PH, Nuijens JH.

Eur J Biochem. 2004 Feb;271(4):678-84.

25.

N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits.

Koles K, van Berkel PH, Pieper FR, Nuijens JH, Mannesse ML, Vliegenthart JF, Kamerling JP.

Glycobiology. 2004 Jan;14(1):51-64. Epub 2003 Sep 26.

PMID:
14514717
26.

Analytical cation-exchange chromatography to assess the identity, purity, and N-terminal integrity of human lactoferrin.

van Veen HA, Geerts ME, van Berkel PH, Nuijens JH.

Anal Biochem. 2002 Oct 1;309(1):60-6.

PMID:
12381362
27.

Characterization of monoclonal antibodies against human lactoferrin.

van Berkel PH, van Veen HA, Geerts ME, Nuijens JH.

J Immunol Methods. 2002 Sep 15;267(2):139-50.

PMID:
12165435
28.

Large scale production of recombinant human lactoferrin in the milk of transgenic cows.

van Berkel PH, Welling MM, Geerts M, van Veen HA, Ravensbergen B, Salaheddine M, Pauwels EK, Pieper F, Nuijens JH, Nibbering PH.

Nat Biotechnol. 2002 May;20(5):484-7.

PMID:
11981562
29.

Enhanced Th1 response to Staphylococcus aureus infection in human lactoferrin-transgenic mice.

Guillén C, McInnes IB, Vaughan DM, Kommajosyula S, Van Berkel PH, Leung BP, Aguila A, Brock JH.

J Immunol. 2002 Apr 15;168(8):3950-7.

30.

Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria.

Nibbering PH, Ravensbergen E, Welling MM, van Berkel LA, van Berkel PH, Pauwels EK, Nuijens JH.

Infect Immun. 2001 Mar;69(3):1469-76.

31.

Charge modification of plasma and milk proteins results in antiviral active compounds.

Swart PJ, Harmsen MC, Kuipers ME, Van Dijk AA, Van Der Strate BW, Van Berkel PH, Nuijens JH, Smit C, Witvrouw M, De Clercq E, de Béthune MP, Pauwels R, Meijer DK.

J Pept Sci. 1999 Dec;5(12):563-76.

PMID:
10628656
32.

Role of the first N-terminal basic cluster of human lactoferrin (R2R3R4R5) in the interactions with the Jurkat human lymphoblastic T-cells.

Legrand D, van Berkel PH, Salmon V, van Veen HA, Slomianny MC, Nuijens JH, Spik G.

Adv Exp Med Biol. 1998;443:49-55.

PMID:
9781342
33.

The N-terminal Arg2, Arg3 and Arg4 of human lactoferrin interact with sulphated molecules but not with the receptor present on Jurkat human lymphoblastic T-cells.

Legrand D, van Berkel PH, Salmon V, van Veen HA, Slomianny MC, Nuijens JH, Spik G.

Biochem J. 1997 Nov 1;327 ( Pt 3):841-6.

34.

N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA.

van Berkel PH, Geerts ME, van Veen HA, Mericskay M, de Boer HA, Nuijens JH.

Biochem J. 1997 Nov 15;328 ( Pt 1):145-51.

35.

Characterization of recombinant human lactoferrin secreted in milk of transgenic mice.

Nuijens JH, van Berkel PH, Geerts ME, Hartevelt PP, de Boer HA, van Veen HA, Pieper FR.

J Biol Chem. 1997 Mar 28;272(13):8802-7.

36.

Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants.

van Berkel PH, van Veen HA, Geerts ME, de Boer HA, Nuijens JH.

Biochem J. 1996 Oct 1;319 ( Pt 1):117-22.

37.

Structure and biological actions of lactoferrin.

Nuijens JH, van Berkel PH, Schanbacher FL.

J Mammary Gland Biol Neoplasia. 1996 Jul;1(3):285-95. Review.

PMID:
10887502
39.

Effect of ploidy on transcription levels in cultured rat aortic smooth muscle cells.

van Neck JW, van Berkel PH, Telleman P, Steijns LS, Onnekink C, Bloemers HP.

FEBS Lett. 1992 Feb 3;297(1-2):189-95.

Supplemental Content

Loading ...
Support Center